Literature DB >> 7031668

Anti-K562 cell monoclonal antibodies recognize hematopoietic progenitors.

N S Young, S P Hwang-Chen.   

Abstract

The K562 leukemia cell has properties of self-renewal and pluripotency similar to those of the hematopoietic stem cell. Monoclonal antibodies to K562 cells have been produced by using hybridoma technology. By radioimmunoassay, some anti-K562 cell antibodies also bind to erythrocyte antigens or peripheral blood mononuclear cells; others are more specific for K562 cells. Antibody binding to hematopoietic progenitors was assayed by using the ability of these cells to form colonies in vitro. After exposure of human bone marrow cells to anti-K562 antibodies and complement, myeloid or erythroid colony formation was inhibited. Some of the inhibitory antibodies showed little binding to mature blood cells by radioimmunoassay, immunofluorescence, and complement cytotoxicity, suggesting that they recognize antigens specific to undifferentiated cells. With the fluorescence-activated cell sorter, one inhibitory antibody was shown to stain only 3% of bone marrow cells. Inhibitory anti-K562 antibodies also bind to myelogenous leukemia cells and virus-transformed lymphocytes. Thus, these antibodies appear to recognize antigens shared by normal hematopoietic progenitors, leukemic cells, and transformed lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7031668      PMCID: PMC349197          DOI: 10.1073/pnas.78.11.7073

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells.

Authors:  A W Burgess; E M Wilson; D Metcalf
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

3.  Technical aspects of the rosette tests used to detect human complement receptor (B) and sheep erythrocyte-binding (T) lymphocytes.

Authors:  N F Mendes; M E Tolnai; N P Silveira; R B Gilbertsen; R S Metzgar
Journal:  J Immunol       Date:  1973-09       Impact factor: 5.422

4.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  Fluorescence activated cell sorting.

Authors:  W A Bonner; H R Hulett; R G Sweet; L A Herzenberg
Journal:  Rev Sci Instrum       Date:  1972-03       Impact factor: 1.523

Review 6.  Aplastic anemia: research themes and clinical issues.

Authors:  N Young
Journal:  Prog Hematol       Date:  1981

7.  Human marrow erythropoiesis in culture. I. Characterization of methylcellulose colony assay.

Authors:  M Ogawa; R T Parmley; H L Bank; S S Spicer
Journal:  Blood       Date:  1976-09       Impact factor: 22.113

8.  Blast crisis of chronic myeloid leukaemia (CML). II. Cell surface marker analysis of "lymphoid" and myeloid cases.

Authors:  G Janossy; M F Greaves; T Revesz; T A Lister; M Roberts; J Durrant; B Kirk; D Catovsky; M E Beard
Journal:  Br J Haematol       Date:  1976-10       Impact factor: 6.998

9.  Ultrastructural localization of peroxidase activity in human platelets and megakaryocytes.

Authors:  J Breton-Gorius; J Guichard
Journal:  Am J Pathol       Date:  1972-02       Impact factor: 4.307

10.  Erythroid colony formation in cultures of human marrow: effect of leukocyte conditioned medium.

Authors:  M T Aye
Journal:  J Cell Physiol       Date:  1977-04       Impact factor: 6.384

View more
  1 in total

1.  Antigenically distinct subpopulations of myeloid progenitor cells (CFU-GM) in human peripheral blood and marrow.

Authors:  D Ferrero; H E Broxmeyer; G L Pagliardi; S Venuta; B Lange; S Pessano; G Rovera
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.